We are all expecting a COVID-19 vaccine that could possibly end the pandemic that has killed more than 330,000 people. Now the first vaccine candidate from China has finished its phase-1 trial on humans, and the results have been put online for everyone to examine. The Lancet, a respecte...
A phase 2 trial of an Ad5 vectoredCOVID-19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research published inThe Lancet. The randomized trial sought to evaluate the safety and immunogenicity of the vaccine candida...
AstraZeneca has signed agreements with governments around the globe to supply the vaccine if the results prove effective. The vaccine is currently in a combined Phase II/III trial in UK and Phase III trials in Brazil and South Africa.
The development of an effective COVID-19 vaccine is of utmost importance. Most vaccine designs can be classified into three camps: protein based (inactivated vaccines, protein subunit, VLP and T-cell based vaccines), gene based (DNA or RNA vaccines, replicating or non-replicating viral/bacterial...
Good news! On July 20th, The Lancet published two papers online at the same time, revealing the results of clinical trials for two COVID-19 vaccines. From China and the United Kingdom respectively, the two stars on the track of adenovirus vector vaccine display a one-on-one competition. ...
Franco-Austrian biotech lab Valneva announced Monday positive results from clinical trials of its COVID vaccine candidate, a month after the UK government terminated a supply deal with the company. Britain had ordered 100 million doses of the vaccine for 2021-2022—the only order so far for Val...
根据第二段中"The data shows that the vaccine, Corona Vac, has produced a very quick and strong immune response and did not cause any severe side effects among the 700 people tested.(数据显示,在接受测试的700人中,这种名为Corona Vac的疫苗已经产生了非常迅速和强烈的免疫反应,并且没有造成任何严重...
COVID-19 VACCINE SHOWS GOOD RESULTS IN CLINICAL TRIALS2020-06-17 21:05:54 看看新闻Knews综合关键词: COVID-19VACCINERESULTSCLINICALTRIALS民生信息Shanghai Live上海国际频道全部评论 请先登录后发表评论 暂无评论,快来发表你的评论吧 推荐视频 00:08 马斯克遭美军方审查 涉嫌违反保密协议 一眼看天下2天前...
Interim results of the Oxford COVID-19 vaccine trials find that the vaccine protects against symptomatic disease in 70% of cases—with vaccine efficacy of 62% for those given two full doses, and of 90% in those given a half then a full dose (both trial arms pre-specified in the pooled...
The long-anticipated interim results of a Phase 3 clinical trial on Johnson & Johnson’s COVID-19 vaccine candidate have been released. The University of Kentucky, in partnership with Baptist Health Lexington and Norton Healthcare in Louisville, are sites for the Janssen Pharmaceutical Companies o...